Mary E Fedor1, Arye Rubinstein. 1. Department of Microbiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York 10461, USA. maryofw@yahoo.com
Abstract
BACKGROUND: Corticosteroids are agents that suppress the immune system. Their suppressive activity is predominantly restricted to cell-mediated immunity, with a marginal inhibitory effect on humoral immunity. OBJECTIVE: To describe an acquired reversible B-cell deficiency in a patient treated with low-dose corticosteroids for 36 years. METHODS: A broad range of T- and B-cell parameters were studied over time, during and after discontinuation of corticosteroid therapy. Published works on this topic in animal and human models are reviewed. The findings unique to this patient are highlighted. RESULTS: While undergoing long-term corticosteroid therapy, a patient developed a clinical and immunologic picture suggestive of common variable immunodeficiency, with predominantly qualitative and quantitative B-cell abnormalities. These abnormalities resolved within 2 years after tapering of corticosteroid therapy. CONCLUSIONS: Long-term low-dose corticosteroid use may reversibly decrease B-cell counts and specific antibody responses.
BACKGROUND: Corticosteroids are agents that suppress the immune system. Their suppressive activity is predominantly restricted to cell-mediated immunity, with a marginal inhibitory effect on humoral immunity. OBJECTIVE: To describe an acquired reversible B-cell deficiency in a patient treated with low-dose corticosteroids for 36 years. METHODS: A broad range of T- and B-cell parameters were studied over time, during and after discontinuation of corticosteroid therapy. Published works on this topic in animal and human models are reviewed. The findings unique to this patient are highlighted. RESULTS: While undergoing long-term corticosteroid therapy, a patient developed a clinical and immunologic picture suggestive of common variable immunodeficiency, with predominantly qualitative and quantitative B-cell abnormalities. These abnormalities resolved within 2 years after tapering of corticosteroid therapy. CONCLUSIONS: Long-term low-dose corticosteroid use may reversibly decrease B-cell counts and specific antibody responses.
Authors: E K Page; A J Page; J Kwun; A C Gibby; F Leopardi; J B Jenkins; E A Strobert; M Song; R A Hennigar; N Iwakoshi; S J Knechtle Journal: Am J Transplant Date: 2012-07-09 Impact factor: 8.086
Authors: Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz Journal: J Allergy Clin Immunol Pract Date: 2015-11-07
Authors: Suzan P van Mens; Sabine C A Meijvis; Jan C Grutters; Bart J M Vlaminckx; Willem J W Bos; Ger T Rijkers Journal: Clin Vaccine Immunol Date: 2012-02-29
Authors: Marilisa Novacco; Felicitas S Boretti; Godelind A Wolf-Jäckel; Barbara Riond; Marina L Meli; Barbara Willi; Hans Lutz; Regina Hofmann-Lehmann Journal: Vet Res Date: 2011-04-20 Impact factor: 3.683